{"id":"https://openalex.org/W7116842226","doi":"https://doi.org/10.1097/cad.0000000000001798","title":"Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity","display_name":"Survival advantage of bevacizumab rechallenge in recurrent ovarian cancer regardless of platinum sensitivity","publication_year":2025,"publication_date":"2025-12-23","ids":{"openalex":"https://openalex.org/W7116842226","doi":"https://doi.org/10.1097/cad.0000000000001798","pmid":"https://pubmed.ncbi.nlm.nih.gov/41430637"},"language":"en","primary_location":{"id":"doi:10.1097/cad.0000000000001798","doi":"https://doi.org/10.1097/cad.0000000000001798","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cad.0000000000001798","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005793653","display_name":"Ugur Ozberk","orcid":"https://orcid.org/0009-0005-9030-022X","observed_orcids":["https://orcid.org/0009-0005-9030-022X"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Ugur Ozberk","raw_affiliation_strings":["Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075032325","display_name":"Seli\u0307n Akt\u00fcrk Esen","orcid":"https://orcid.org/0000-0002-3426-9505","observed_orcids":["https://orcid.org/0000-0002-3426-9505"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Selin Akturk Esen","raw_affiliation_strings":["Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050239706","display_name":"Serhat Sekmek","orcid":"https://orcid.org/0000-0003-4650-248X","observed_orcids":["https://orcid.org/0000-0003-4650-248X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Serhat Sekmek","raw_affiliation_strings":["Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052602372","display_name":"\u0130smet Seven","orcid":"https://orcid.org/0009-0001-4706-0495","observed_orcids":["https://orcid.org/0009-0001-4706-0495"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ismet Seven","raw_affiliation_strings":["Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000708665","display_name":"\u00d6znur Bal","orcid":"https://orcid.org/0000-0002-6901-2646","observed_orcids":["https://orcid.org/0000-0002-6901-2646"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Oznur Bal","raw_affiliation_strings":["Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036701142","display_name":"Efnan Algin","orcid":"https://orcid.org/0000-0002-8917-9267","observed_orcids":["https://orcid.org/0000-0002-8917-9267"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Efnan Algin","raw_affiliation_strings":["Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Sebnem Yucel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sebnem Yucel","raw_affiliation_strings":["Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033820961","display_name":"Do\u011fan Uncu","orcid":"https://orcid.org/0000-0002-0929-3271","observed_orcids":["https://orcid.org/0000-0002-0929-3271"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dogan Uncu","raw_affiliation_strings":["Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5005793653"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.7001,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.7743772,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"37","issue":"6","first_page":"359","last_page":"365"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.949999988079071},{"id":"https://openalex.org/keywords/recurrent-ovarian-cancer","display_name":"recurrent ovarian cancer","score":0.7639999985694885},{"id":"https://openalex.org/keywords/platinum-sensitivity","display_name":"platinum sensitivity","score":0.5830000042915344},{"id":"https://openalex.org/keywords/platinum-resistance","display_name":"platinum resistance","score":0.871999979019165},{"id":"https://openalex.org/keywords/second-line-chemotherapy","display_name":"second-line chemotherapy","score":0.7360000014305115},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9710000157356262},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9980000257492065},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.7549999952316284},{"id":"https://openalex.org/keywords/epithelial-ovarian-cancer","display_name":"epithelial ovarian cancer","score":0.718999981880188}],"concepts":[{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.9750999808311462},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9222999811172485},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7353000044822693},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6916999816894531},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.6794999837875366},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6015999913215637},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.5002999901771545},{"id":"https://openalex.org/C2992773878","wikidata":"https://www.wikidata.org/wiki/Q7645976","display_name":"Epithelial ovarian cancer","level":4,"score":0.49889999628067017},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.47780001163482666},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4327000081539154},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.4230000078678131},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.3734999895095825},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.3294000029563904},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3276999890804291},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.3248000144958496},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.32199999690055847},{"id":"https://openalex.org/C3018023364","wikidata":"https://www.wikidata.org/wiki/Q425265","display_name":"Significant difference","level":2,"score":0.2948000133037567},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.27959999442100525},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2768999934196472},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.2526000142097473}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000074322","descriptor_name":"Antineoplastic Agents, Immunological","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000077216","descriptor_name":"Carcinoma, Ovarian Epithelial","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000077216","descriptor_name":"Carcinoma, Ovarian Epithelial","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D000077216","descriptor_name":"Carcinoma, Ovarian Epithelial","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D000077982","descriptor_name":"Progression-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D010051","descriptor_name":"Ovarian Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/cad.0000000000001798","doi":"https://doi.org/10.1097/cad.0000000000001798","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cad.0000000000001798","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},{"id":"pmid:41430637","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/41430637","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.67061847448349,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W2113122060","https://openalex.org/W2135947389","https://openalex.org/W2160373161","https://openalex.org/W2170928115","https://openalex.org/W2171658624","https://openalex.org/W3128856576","https://openalex.org/W3181453599","https://openalex.org/W3211196596","https://openalex.org/W4393258188","https://openalex.org/W4407856756","https://openalex.org/W4407943466","https://openalex.org/W4410417087","https://openalex.org/W4413293836"],"related_works":[],"abstract_inverted_index":{"Bevacizumab":[0,200],"has":[1],"demonstrated":[2],"significant":[3,195],"efficacy":[4,37],"in":[5,26,45,130,182,220],"both":[6,151,228],"first-line":[7,72,204,251],"and":[8,77,110,118,153,230,243],"recurrent":[9,46,63,221],"settings":[10],"of":[11,20,38,51,161,212,248],"epithelial":[12,64],"ovarian":[13,48,65,222],"cancer;":[14],"however,":[15],"evidence":[16],"regarding":[17],"the":[18,36,131,136,183,190,245],"benefit":[19,147],"bevacizumab":[21,39,132,162,184,249],"retreatment":[22,40,201],"after":[23,124],"prior":[24,203],"exposure":[25],"real-world":[27],"populations":[28],"remains":[29],"limited.":[30],"This":[31,55,146],"study":[32,58],"aimed":[33],"to":[34,84,239],"evaluate":[35],"compared":[41,134],"with":[42,62,135,208,233],"nonbevacizumab":[43,137],"regimens":[44],"metastatic":[47],"carcinoma,":[49],"irrespective":[50],"platinum":[52,213],"sensitivity":[53],"status.":[54],"retrospective":[56],"single-center":[57],"included":[59],"133":[60],"patients":[61,232],"cancer":[66],"who":[67],"had":[68],"previously":[69],"received":[70],"bevacizumab-containing":[71,87],"therapy":[73],"between":[74],"January":[75],"2015":[76],"May":[78],"2025.":[79],"Patients":[80,100],"were":[81,105,114],"grouped":[82],"according":[83],"second-line":[85,125],"treatment:":[86],"chemotherapy":[88,94],"(":[89,96,196],"n":[90,97],"=":[91,98,169,198],"51)":[92],"or":[93],"alone":[95],"82).":[99],"undergoing":[101],"secondary":[102],"cytoreductive":[103],"surgery":[104],"excluded.":[106],"Progression-free":[107],"survival":[108,112,218],"(PFS)":[109],"overall":[111],"(OS)":[113],"analyzed":[115],"using":[116],"Kaplan-Meier":[117],"Cox":[119],"regression":[120],"models.":[121],"Median":[122],"PFS-2":[123,166],"treatment":[126],"was":[127,148,179,192,206],"significantly":[128],"longer":[129,181],"group":[133,138,185],"(9.7":[139],"vs.":[140,187],"3.0":[141],"months;":[142],"P":[143,174,197],"<":[144,175],"0.001).":[145,176],"consistent":[149],"across":[150],"platinum-sensitive":[152,229],"platinum-resistant":[154,231],"subgroups.":[155],"Multivariate":[156],"analysis":[157],"confirmed":[158],"that":[159],"omission":[160],"independently":[163],"predicted":[164],"worse":[165],"(hazard":[167],"ratio":[168],"3.33,":[170],"95%":[171],"CI:":[172],"2.17-5.11,":[173],"Although":[177],"OS-2":[178],"numerically":[180],"(14.1":[186],"8.2":[188],"months),":[189],"difference":[191],"not":[193],"statistically":[194],"0.091).":[199],"following":[202],"use":[205,247],"associated":[207],"improved":[209],"PFS":[210],"regardless":[211],"sensitivity,":[214],"suggesting":[215],"a":[216],"potential":[217],"advantage":[219],"cancer.":[223],"Prospective,":[224],"randomized":[225],"studies":[226],"including":[227],"larger":[234],"sample":[235],"sizes":[236],"are":[237],"warranted":[238],"confirm":[240],"these":[241],"findings":[242],"determine":[244],"optimal":[246],"beyond":[250],"therapy.":[252]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-12-23T00:00:00"}